Literature DB >> 18279771

Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation.

Gad Cotter1, Marco Metra, Olga Milo-Cotter, Howard C Dittrich, Mihai Gheorghiade.   

Abstract

Although fluid overload is one of the most prominent features of acute heart failure (AHF), its mechanism remains challenging, due to the lack of consistent data from prospective studies. Traditionally, fluid overload was thought to be mainly the result of either increased intake of fluid and salt or non-adherence with diuretic therapy. However, recent data showed little weight change before or during an AHF event suggesting that in many cases fluid overload is caused by other mechanisms such as fluid redistribution and neurohormonal or inflammatory activation. Redistribution may be the result of a combined vascular and cardiac process reducing capacitance in the venous system (and hence increasing preload) and increasing arterial stiffness and resistance (and hence afterload). When these vascular processes occur acutely and are superimposed on reduced cardiac function; fluid is redistributed to the lungs instigating pulmonary congestion. In this paper we elaborate on this possible pathophysiological mechanism and review its potential causes and amplifiers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18279771     DOI: 10.1016/j.ejheart.2008.01.007

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  79 in total

Review 1.  Emerging therapies for heart failure: renal mechanisms and effects.

Authors:  Amir Kazory; Edward A Ross
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

2.  Serelaxin, a 'breakthrough' investigational intravenous agent for acute heart failure.

Authors:  Marta A Miyares; Kyle A Davis
Journal:  P T       Date:  2013-10

3.  Non-invasive Ventilation: A Gimmick or Does it Really Affect Outcomes?

Authors:  Tiffany S Behringer; Sean Collins
Journal:  Curr Emerg Hosp Med Rep       Date:  2015-06

Review 4.  Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents.

Authors:  Marco Metra; Luca Bettari; Valentina Carubelli; Silvia Bugatti; Alessandra Dei Cas; Francesca Del Magro; Valentina Lazzarini; Carlo Lombardi; Livio Dei Cas
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

Review 5.  Kidney disease in heart failure: the importance of novel biomarkers for type 1 cardio-renal syndrome detection.

Authors:  Alberto Palazzuoli; Peter A McCullough; Claudio Ronco; Ranuccio Nuti
Journal:  Intern Emerg Med       Date:  2015-05-14       Impact factor: 3.397

Review 6.  Relaxin: review of biology and potential role in treating heart failure.

Authors:  Sam L Teichman; Elaine Unemori; John R Teerlink; Gad Cotter; Marco Metra
Journal:  Curr Heart Fail Rep       Date:  2010-06

7.  Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study.

Authors:  Marco Metra; John R Teerlink; G Michael Felker; Barry H Greenberg; Gerasimos Filippatos; Piotr Ponikowski; Sam L Teichman; Elaine Unemori; Adriaan A Voors; Beth Davison Weatherley; Gad Cotter
Journal:  Eur J Heart Fail       Date:  2010-08-22       Impact factor: 15.534

8.  Optogenetic in vivo cell manipulation in KillerRed-expressing zebrafish transgenics.

Authors:  Cathleen Teh; Dmitry M Chudakov; Kar-Lai Poon; Ilgar Z Mamedov; Jun-Yan Sek; Konstantin Shidlovsky; Sergey Lukyanov; Vladimir Korzh
Journal:  BMC Dev Biol       Date:  2010-11-02       Impact factor: 1.978

Review 9.  Relaxin, a pleiotropic vasodilator for the treatment of heart failure.

Authors:  Sam L Teichman; Elaine Unemori; Thomas Dschietzig; Kirk Conrad; Adriaan A Voors; John R Teerlink; G Michael Felker; Marco Metra; Gad Cotter
Journal:  Heart Fail Rev       Date:  2008-12-20       Impact factor: 4.214

Review 10.  Vasodilators in the treatment of acute heart failure: what we know, what we don't.

Authors:  Marco Metra; John R Teerlink; Adriaan A Voors; G Michael Felker; Olga Milo-Cotter; Beth Weatherley; Howard Dittrich; Gad Cotter
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.